US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Veraxa Biotech Holding AG

1.38

-0.0200-1.43%

Post-market: 1.410.0282+2.04%19:30 EDT

Volume:176.25K

Turnover:246.70K

Market Cap:195.14M

PE:6.44

High:1.44

Open:1.42

Low:1.36

Close:1.40

52wk High:27.36

52wk Low:1.27

Shares:141.41M

Float Shares:41.01M

Volume Ratio:0.46

T/O Rate:0.43%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.2142

EPS(LYR):-5.8037

ROE:-871.42%

ROA:-49.99%

PB:-10.06

PE(LYR):-0.24

Loading ...

Overview Company News Filings

Veraxa Biotech CEO Christoph Antz Reports Purchase of 5,000 Shares for $7,650

VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase

VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision

Veraxa Biotech Ag: Successful in Vitro Proof-of-Concept Study Shows Potential to Create Novel Aocs by Combining Both Parties’ Tech & Expertise

THOMSON REUTERS

Veraxa Biotech Ag: Co & Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate Alliance

THOMSON REUTERS

Veraxa Biotech, Secarna announce initial results from AOC alliance

Veraxa Biotech, Secarna Hit in Vitro Milestone in Antibody-Oligonucleotide Conjugate Alliance

Veraxa Biotech Files Form 3 for Interim CFO Carl Von Halem

VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies

Veraxa Biotech Holding Ag - Files to Register Resale of up to 25 Mln Ordinary Shares - SEC Filing

THOMSON REUTERS

Veraxa Biotech Files First BiTAC-related Patent Applications for Cancer Therapy Platforms

VERAXA Biotech (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform

Veraxa Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

THOMSON REUTERS

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures

VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration

Veraxa Biotech advances VXA-222 following milestone in OmniAb pact

Veraxa Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program Vxa-222 from Joint Discovery Collaboration with OmniAb

THOMSON REUTERS

Veraxa Biotech Shareholders Approved All Proposals at Extraordinary General Meeting

Veraxa Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/VRXA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VRXA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","market":"US","secType":"STK","nameCN":"Veraxa Biotech Holding AG","latestPrice":1.38,"timestamp":1788379200000,"preClose":1.4,"halted":0,"volume":176250,"hourTrading":{"tag":"盘后","latestPrice":1.4082,"preClose":1.38,"latestTime":"19:30 EDT","volume":1711,"amount":2407.1283917,"timestamp":1788391803184,"change":0.0282,"changeRate":0.020435,"amplitude":0.020435},"delay":0,"changeRate":-0.0142857142857143,"floatShares":41012504,"shares":141407813,"eps":0.2142,"marketStatus":"Post-Mkt","change":-0.02,"latestTime":"09-02 19:43:36 EDT","open":1.42,"high":1.435,"low":1.36,"amount":246703.3995,"amplitude":0.053571,"askPrice":1.52,"askSize":9044,"bidPrice":1.38,"bidSize":40,"shortable":3,"etf":0,"ttmEps":0.2142,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788393600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.4,"preHourTrading":{"tag":"盘前","latestPrice":1.414,"preClose":1.4,"latestTime":"08:13 EDT","volume":4223,"amount":6365.2544198,"timestamp":1788351217777,"change":0.014,"changeRate":0.01,"amplitude":0.121429},"postHourTrading":{"tag":"盘后","latestPrice":1.4082,"preClose":1.38,"latestTime":"19:30 EDT","volume":1711,"amount":2407.1283917,"timestamp":1788391803184,"change":0.0282,"changeRate":0.020435,"amplitude":0.020435},"volumeRatio":0.459351},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","floatShares":41012504,"roa":"-49.99%","roe":"-871.42%","lyrEps":-5.803658,"volumeRatio":0.459351,"shares":141407813,"dividePrice":0,"high":1.435,"amplitude":0.053571,"preClose":1.4,"low":1.36,"week52Low":1.27,"pbRate":"-10.06","psRate":"6772.80","week52High":27.36,"institutionHeld":0,"latestPrice":1.38,"committee":-0.991193,"eps":0.2142,"divideRate":0,"volume":176250,"delay":0,"ttmEps":0.2142,"open":1.42,"prevYearClose":18.65,"prevWeekClose":1.35,"prevMonthClose":1.35,"prevQuarterClose":1.88,"fiveDayClose":1.64,"twentyDayClose":1.82},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VRXA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VRXA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VRXA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VRXA","date":"2026-09-01","current":6.442577,"percent":0.875,"low":-1.401348,"twenty":-1.340461,"median":-1.249249,"eighty":-0.788262,"high":-0.413162,"avg":-1.073718,"sd":0.366604,"marketCap":34043375},"quantilePoints":[{"date":"2026-08-21","current":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"marketCap":47660725},{"date":"2026-08-28","current":-1.03732,"twenty":-1.349054,"median":-1.281094,"eighty":-1.194963,"marketCap":36312933},{"date":"2026-09-01","current":-0.414674,"twenty":-1.340461,"median":-1.249249,"eighty":-0.788262,"marketCap":34043375}],"updateTime":1788392616803},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VRXA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664888755","title":"Veraxa Biotech CEO Christoph Antz Reports Purchase of 5,000 Shares for $7,650","url":"https://stock-news.laohu8.com/highlight/detail?id=2664888755","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664888755?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:10","pubTimestamp":1788207055,"startTime":"0","endTime":"0","summary":"Veraxa Biotech CEO Christoph Antz reports purchase of 5,000 shares for $7,650Veraxa Biotech CEO, director Christoph Rudiger Antz reported a purchase of 5,000 ordinary shares.The shares were bought at ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL5ghMkz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Veraxa Biotech CEO Christoph Antz Reports Purchase of 5,000 Shares for $7,650","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662530737","title":"VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2662530737","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662530737?lang=en_us&edition=fundamental","pubTime":"2026-08-25 23:00","pubTimestamp":1787670008,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, August 25th, 2026, FinanceWire Following completion of the initial phase of its collaboration with OmniAb, VERAXA wil...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-vxa-222-cancer-program-beyond-discovery-phase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-vxa-222-cancer-program-beyond-discovery-phase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQY","ONEQ","XBI","IYW","JEPQ","QYLG","BK4588","QLD","QQQA","QQQJ","BK4585","QDTE","NQmain","PSQ","QID",".IXIC","QQQY","TECS","TQQQ","NVIW.SI","MNQmain","QQQE","BK4139","QQQM","BK4581","QQQ","GPIQ","VRXA","SQQQ","FTEC","NDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662083312","title":"VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision","url":"https://stock-news.laohu8.com/highlight/detail?id=2662083312","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662083312?lang=en_us&edition=fundamental","pubTime":"2026-08-25 01:00","pubTimestamp":1787590833,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, August 24th, 2026, FinanceWire VERAXA Biotech is changing how antibody-based therapies recognize and attack cancer ce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-builds-antibody-based-cancer-pipeline-around-dual-targeting-precision?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-builds-antibody-based-cancer-pipeline-around-dual-targeting-precision?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQQ","QYLG","PSQ","QQQE","BK4588","MNQmain",".IXIC","GPIQ","QQQY","QID","QLD","XBI","ONEQ","JEPQ","IYW","NQmain","QQQA","QQQM","SQQQ","TQQY","NVIW.SI","QDTE","NDX","FTEC","BK4581","QQQ","BK4139","VRXA","QQQJ","TECS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661427591","title":"Veraxa Biotech Ag: Successful in Vitro Proof-of-Concept Study Shows Potential to Create Novel Aocs by Combining Both Parties’ Tech & Expertise","url":"https://stock-news.laohu8.com/highlight/detail?id=2661427591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661427591?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:41","pubTimestamp":1787571679,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L08R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661275959","title":"Veraxa Biotech Ag: Co & Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate Alliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275959","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275959?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:41","pubTimestamp":1787571679,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L08R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661727583","title":"Veraxa Biotech, Secarna announce initial results from AOC alliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2661727583","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661727583?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:16","pubTimestamp":1787570169,"startTime":"0","endTime":"0","summary":"Veraxa Biotech (VRXA) and Secarna Pharmaceuticals announced initial results from their strategic research collaboration to develop next-generation ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-secarna-announce-initial-results-from-aoc-alliance-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-secarna-announce-initial-results-from-aoc-alliance-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VRXA","BK4139","BK4588","BK4581","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661273390","title":"Veraxa Biotech, Secarna Hit in Vitro Milestone in Antibody-Oligonucleotide Conjugate Alliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273390","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273390?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569224,"startTime":"0","endTime":"0","summary":"Veraxa Biotech, Secarna hit in vitro milestone in antibody-oligonucleotide conjugate allianceVeraxa Biotech entered a strategic research collaboration with Secarna to develop antibody oligonucleotide ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL9ymxP3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","LU2210149790.SGD","LU2095319765.USD","BK4139","IE00B3QW5Z07.USD","LU0314104364.USD","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BQXX3C00.GBP","SG9999014005.SGD","SG9999014039.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","SG9999014013.SGD","VRXA","BK4588","IE00BN0W2T93.GBP","BK4112","IE00BQXX3F31.USD","SG9999014021.USD","IE00BQXX3D17.EUR","BCDF","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661234428","title":"Veraxa Biotech Files Form 3 for Interim CFO Carl Von Halem","url":"https://stock-news.laohu8.com/highlight/detail?id=2661234428","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661234428?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:00","pubTimestamp":1787256059,"startTime":"0","endTime":"0","summary":"Veraxa Biotech files Form 3 for Interim CFO Carl von HalemInterim CFO Carl von Halem filed an initial Form 3 for Veraxa Biotech AG, dated July 10, 2026.Disclaimer:This news brief was created by Public","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL7C4F43:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656766","title":"VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656766","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656766?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:00","pubTimestamp":1786035614,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, August 6th, 2026, FinanceWire The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC&r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-vxa-222-cancer-program-while-expanding-patent-portfolio-for-next-generation-antibody-technologies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-vxa-222-cancer-program-while-expanding-patent-portfolio-for-next-generation-antibody-technologies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NDX","TECS","BK4588","QDTE","NVIW.SI","QLD","NQmain","QQQJ","QQQY","TQQQ","QYLG","BK4139","FTEC","BK4585","QQQE","GPIQ","PSQ","VRXA","IYW","QQQ",".IXIC","QQQA","XBI","ONEQ","SQQQ","QQQM","QID","JEPQ","MNQmain","BK4581","TQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656917923","title":"Veraxa Biotech Holding Ag - Files to Register Resale of up to 25 Mln Ordinary Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2656917923","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656917923?lang=en_us&edition=fundamental","pubTime":"2026-08-01 05:14","pubTimestamp":1785532463,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X2AR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656399655","title":"Veraxa Biotech Files First BiTAC-related Patent Applications for Cancer Therapy Platforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399655","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656399655?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:06","pubTimestamp":1785528362,"startTime":"0","endTime":"0","summary":"Veraxa Biotech files first BiTAC-related patent applications for cancer therapy platformsVeraxa Biotech filed its first BiTAC-related patent applications in H1 2026 covering composition of matter for ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL5xBfbf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655807507","title":"VERAXA Biotech (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2655807507","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655807507?lang=en_us&edition=fundamental","pubTime":"2026-07-31 01:30","pubTimestamp":1785432641,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 30th, 2026, FinanceWire The company has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-strengthens-scientific-leadership-as-new-cso-takes-the-helm-in-advancing-bitacr-cancer-therapy-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-strengthens-scientific-leadership-as-new-cso-takes-the-helm-in-advancing-bitacr-cancer-therapy-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONEQ","QYLG","TQQQ","NQmain","VRXA","BK4588","R","BK4585","PSQ","GPIQ","NVIW.SI","BK4232","BK4022","SQQQ","QLD","QQQ","QQQA","TECS","IYW","QQQM","JEPQ","FTEC","MNQmain","BK4581","TQQY","QDTE","QQQE",".IXIC","QQQY","BK4139","XBI","NDX","QID","QQQJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655861707","title":"Veraxa Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2655861707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655861707?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUABGQ6NH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655686238","title":"VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2655686238","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655686238?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322800,"startTime":"0","endTime":"0","summary":"First BiTAC-related patent applications filed in H1 2026 including patents covering composition of matter and proprietary payload platform, with additional patents secured in contributing technology a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/29/3335104/0/en/VERAXA-Biotech-Strengthens-Patent-Portfolio-to-Protect-Core-Technology-Platforms-and-Product-Candidates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NETL","BK4581","BK4585","BK4588","BK4080","XBI","VRXA","ADC","BK4231","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655446889","title":"VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2655446889","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655446889?lang=en_us&edition=fundamental","pubTime":"2026-07-29 01:00","pubTimestamp":1785258032,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 28th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA) announced that shareholders overwhelmingly approv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-shareholders-approve-corporate-governance-financing-measures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-shareholders-approve-corporate-governance-financing-measures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TQQY","QDTE","FTEC","QQQM","JEPQ","TQQQ","QQQA","XBI","QQQY","QYLG","MNQmain","NVIW.SI","NQmain","ONEQ","BK4585","SQQQ","VRXA","BK4588","QQQJ","GPIQ","TECS","QQQ","IYW","PSQ",".IXIC","QQQE","NDX","BK4581","QLD","QID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654047585","title":"VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2654047585","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654047585?lang=en_us&edition=fundamental","pubTime":"2026-07-28 02:30","pubTimestamp":1785177027,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 27th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA) announced the advancement of its bispecific antibody-d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-bispecific-adc-program-under-omniab-collaboration?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-bispecific-adc-program-under-omniab-collaboration?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","ONEQ","GPIQ","VRXA","MNQmain","BK4581","BK4585","QQQ","TECS",".IXIC","BK4139","QLD","QID","NQmain","QQQJ","BK4080","PSQ","QQQM","QQQE","IYW","BK4588","JEPQ","NDX","NVIW.SI","BK4231","SQQQ","ADC","NETL","QDTE","QQQA","TQQQ","TQQY","QQQY","FTEC","QYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654140440","title":"Veraxa Biotech advances VXA-222 following milestone in OmniAb pact","url":"https://stock-news.laohu8.com/highlight/detail?id=2654140440","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654140440?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:20","pubTimestamp":1785151247,"startTime":"0","endTime":"0","summary":"Veraxa Biotech (VRXA) announced the advancement of bispecific ADC program VXA-222, following successful achievement of a key technical milestone in...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-advances-vxa-222-following-milestone-in-omniab-pact-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-advances-vxa-222-following-milestone-in-omniab-pact-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","VRXA","BK4588","BK4585","BK4581","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654901487","title":"Veraxa Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program Vxa-222 from Joint Discovery Collaboration with OmniAb","url":"https://stock-news.laohu8.com/highlight/detail?id=2654901487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654901487?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA8QKY0T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654032636","title":"Veraxa Biotech Shareholders Approved All Proposals at Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2654032636","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654032636?lang=en_us&edition=fundamental","pubTime":"2026-07-25 04:05","pubTimestamp":1784923546,"startTime":"0","endTime":"0","summary":"Veraxa Biotech shareholders approved all proposals at extraordinary general meetingVeraxa held an extraordinary general meeting today.Shareholders adopted all board proposals.Approved amendments intro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL4hXVm8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014039.USD","NDAQ","BCDF","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU2095319765.USD","SG9999014013.SGD","BK4139","BK4588","SG9999014021.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014005.SGD","BK4112","VRXA","LU0314104364.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654032570","title":"Veraxa Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2654032570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654032570?lang=en_us&edition=fundamental","pubTime":"2026-07-25 04:05","pubTimestamp":1784923500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUA8DP80B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":69,"code":"91000000","status":"200"}]}}